Opera Bioscience, Inc.
Evanston, IL Doing business as Opera Bioscience
- UEI
- GT5QNNN83TQ7
- CAGE
- 94RW1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1801 Maple Ave #6240, Evanston, IL 60201, USA
- Website
- operabioscience.com
- Founded
- 2021
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase II: a gram-negative bacterial secretion platform for cost-effective, high-purity recombinant protein… | National Science Foundation | $1,248,994 | |
| A new platform for inexpensive and scalable recombinant protein and growth factor production to support cell culture… | National Institute of General Medical Sciences | $647,288 | |
| Sbir phase i: a low-cost, bacterial production platform for the manufacturing of high purity recombinant proteins and… | National Science Foundation | $275,000 |
About Opera Bioscience, Inc.
Opera Bioscience, Inc., registered in SAM.gov since July 2021, is a woman-owned small business located in Evanston, Illinois, focused on developing innovative bacterial protein secretion platform technologies. The company specializes in creating cost-effective protein expression systems that enable high-purity recombinant protein production across multiple industries, with a particular emphasis on biomanufacturing, therapeutic development, and advanced biotechnology applications. As a for-profit corporate entity, Opera Bioscience leverages advanced bacterial protein secretion techniques to address manufacturing challenges in protein production, with the goal of reducing costs, improving efficiency, and supporting domestic supply chain resilience.
The company has secured multiple federal grants from agencies like the National Science Foundation (NSF) and the National Institute of General Medical Sciences (NIGMS), primarily through Small Business Innovation Research (SBIR) programs. These grants, totaling approximately $2.1 million, have supported the development of a novel bacterial protein secretion platform with applications in various sectors, including therapeutic protein production, cell culture technologies, and cultivated meat industries. Specifically, Opera Bioscience's projects aim to optimize industrial-scale manufacturing processes for producing recombinant proteins and growth factors, with key objectives including developing scalable protein production workflows, creating cost-effective purification methodologies, and establishing industrially viable production processes. The company's technology has potential broader impacts, such as reducing manufacturing costs for biologic drugs, supporting domestic manufacturing, enabling new production processes in industries like textiles, and potentially revolutionizing protein production for emerging biotechnological applications.
Quick answers
What is Opera Bioscience, Inc.'s UEI?
Opera Bioscience, Inc.'s Unique Entity ID (UEI) in SAM.gov is GT5QNNN83TQ7.
What is Opera Bioscience, Inc.'s CAGE code?
Opera Bioscience, Inc.'s CAGE code is 94RW1.
What is Opera Bioscience, Inc.'s primary NAICS code?
Opera Bioscience, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Opera Bioscience, Inc. located?
Opera Bioscience, Inc.'s physical address in SAM.gov is 1801 Maple Ave #6240, Evanston, IL 60201, USA.
Is Opera Bioscience, Inc. registered in SAM.gov?
Yes. Opera Bioscience, Inc.'s SAM.gov registration is active through March 13, 2027.
What is Opera Bioscience, Inc.'s most recent federal award?
Opera Bioscience, Inc.'s most recent federal grant award is Sbir phase II: a gram-negative bacterial secretion platform for cost-effective, high-purity recombinant protein… (2451468), from National Science Foundation, on June 15, 2025.
On GovTribe
See Opera Bioscience, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors